These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18561503)

  • 21. Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism.
    Chen L; Chen Q; Zhu M; Zhuang Z
    J Coll Physicians Surg Pak; 2021 Mar; 31(3):294-297. PubMed ID: 33775018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
    de Jong LA; van der Velden AWG; Hulst MV; Postma MJ
    BMJ Open; 2020 Nov; 10(11):e039057. PubMed ID: 33444193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
    Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
    Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
    Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
    Abdel-Razeq H; Finianos A; Taher AT
    Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
    Bauersachs RM; Dudenhausen J; Faridi A; Fischer T; Fung S; Geisen U; Harenberg J; Herchenhan E; Keller F; Kemkes-Matthes B; Schinzel H; Spannagl M; Thaler CJ;
    Thromb Haemost; 2007 Dec; 98(6):1237-45. PubMed ID: 18064320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
    Hellgren M; Mistafa O
    J Obstet Gynaecol; 2019 May; 39(4):439-450. PubMed ID: 30426808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective study evaluating safety, clinical effect, and dosing of dalteparin for the treatment of venous thromboembolism in term neonates.
    Sherman N; Younus M; Wolter K; Victor S; Kairamkonda V; Adams E; Brotherton H; Boyle EM
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31215. PubMed ID: 39054689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
    Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
    Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VTE and anti-coagulation therapy in cancer patients.
    Miyazaki Y; Sase K; Hasegawa K; Morimoto T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):189-191. PubMed ID: 31378809
    [No Abstract]   [Full Text] [Related]  

  • 38. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
    McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
    J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.